Board of Directors
Sarah Howell, Ph.D., Chief Executive Officer
Sarah, who joined Arecor in 2011, before being appointed Chief Executive Officer to the Group in 2015, has a strong background in clinical and commercial pharmaceutical product development, manufacture, supply and licensing across a range of product types and therapeutic areas. She has served in a number of leading roles in the pharmaceutical industry, most recently as Vice President for CMC (Chemistry, Manufacturing & Controls) and Technical Development for BTG where she had full responsibility for CMC development and supply across BTG’s diverse portfolio of clinical and commercial products.
Andrew J M Richards, Ph.D., CBE (Chairman)
Andrew J M Richards, Ph.D., CBE (Chairman) Andy is an established biotechnology entrepreneur and investor with broad experience from the UK biotechnology sector in research, drug development, commercial deals and scaling up companies. He is the Chairman of Congenica Ltd, Abcodia Ltd, and Closed Loop Medicine and a director of Owlstone Medical and Ieso Digital Health Ltd. He is Chairman of BBT the Babraham Research Campus and a director of Cancer Research Technology Ltd (the commercial board of Cancer Research UK) and The Scale-Up Institute.
Susan Lowther, Chief Financial Officer and Company Secretary
Susan joined Arecor in 2019 as Chief Financial Officer and Company Secretary. She has significant experience of the life science industry, growing companies and executing M&A transactions. She also has a strong commercial and operational background, with direct responsibility for finance, HR, IT and facilities functions.
Sam Fazeli, Ph.D., Non-Executive Director
Sam has served as a member of our Board of Directors since September 2017 and he brings over nineteen years of experience of conducting equity research as a pharmaceutical analyst, working at firms such as Nomura International and HSBC. Currently, he is Director of EMEA Research and Senior Pharmaceutical Analyst at Bloomberg Intelligence in London, where he specialises in global pharmaceuticals.
Andrew Lane, MA, Non-Executive Director
Andrew joined Unilever as a marketing trainee in 1985 after studying Biochemistry at Cambridge University. He is a founding Director of Unilever Ventures which focuses on investments in Home and Personal Care Technology.
Alan E Smith, Ph.D., FRS, CBE, Non-Executive Director
Alan is the former Senior Vice President and the Chief Scientific Officer of Genzyme Corporation, Cambridge MA, where he had overall responsibility for the company’s science. Prior to its acquisition by Genzyme in 1989, Alan was the vice president and scientific director of Integrated Genetics, a MA start-up biotechnology company. From 1980-84 he was head of the biochemistry division at the National Institute of Medical Research, Mill Hill, London. Presently, Alan sits on the Scientific Advisory Boards of: The Cancer Research Institute in Cambridge UK; Pharnext – a start-up genomics company in Paris, France; and ImmuneXcite – a start-up immunology company, in Lexington MA. He is on the Board of Directors of Advantagene – a start-up gene therapy company in Newton MA.
Jeremy Curnock-Cook, Non-Executive Director
Jeremy is passionate about investing today for a healthier tomorrow and bringing tangible benefits to people across the world.
As a veteran in the life sciences/healthcare industry he has been actively supporting the commercialisation of healthcare innovations and helping entrepreneurs build their international businesses over the past 35 years.
Alexander Crawford MA FCA, Non-Executive Director
Alexander joined Calculus Capital in 2015 as an Investment Director, and has over 20 years’ investment and corporate finance -experience, including senior roles in JP Morgan and Evercore Partners in London, New York and Johannesburg. He has an MA in Mathematics from Cambridge University and qualified as a Chartered Accountant with KPMG.